



Guselkumab

Adjudication Guideline

Table of content

Abstract Adjudication Policy Denial codes Appendices

Abstract

For Members & Medical Professionals:

Guselkumab(Tremfya) is an interluken-23(IL-23) blocker that is indicated for adults with the following conditions:

- Plaque Psoriasis
- Psoriatic Arthritis

Scope

This adjudication rule aims to highlight the medical necessity and coverage details of Guselkumab for all health insurance plans administered by Daman.

Rule Category:
Pharmaceutical

Ref: No:
2022-PH-17

Version Control:
Version No.1.0

Effective Date:
30-01-23

Revision Date:
30-01-24



Approved by:
Daman

Responsible:
Medical Standards & Research

Related Adjudication Guidelines: NA

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.

PUBLIC

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	TEMP/349	Version No.:	1	Revision No.:	1	Date of Issue:	16.07.2019	Page No(s):	1 of 5
---------------	----------	--------------	---	---------------	---	----------------	------------	-------------	--------

Adjudication Policy

Eligibility / Coverage Criteria

Guselkumab(Tremfya) is an interleukin-23(IL-23) blocker that is indicated for adults with the following conditions:

- 1. Plaque Psoriasis (Psoriasis Vulgaris)** is a chronic autoimmune disease that causes thick scaly patches called plaques on the skin. Plaques can appear anywhere on the body but most commonly appears on the elbows, knees, back, and scalp. Severe forms of Psoriasis vulgaris appears on the face, feet, genitals, and extremities

Guselkumab is indicated for cases of Plaque Psoriasis if a patient (above the age of 18) meets one of the following criteria when prescribed by an eligible clinician:

Indication for plaque psoriasis
Moderate to severe form of Psoriasis
Inadequate response to topical therapy
Inadequate response to Systemic Therapy
Contraindications to topical therapy, systemic therapy, and phototherapy

2. Psoriatic Arthritis

Psoriatic arthritis is a chronic inflammatory disease which is characterized by skin changes, Nail changes, peripheral arthritis, and axial disease involvement. Guselkumab is indicated for cases of Psoriatic Arthritis if a patient (above the age of 18) meets one of the following criteria when prescribed by an eligible clinician:

Indication Criteria for Guselkumab for Psoriatic Arthritis
Inadequate response to Systemic Therapy
Contraindications to topical therapy, systemic therapy, and phototherapy

Dosage:

1. Plaque Psoriasis:

Week	Dosage
Week 0	100mg Subcutaneous
Week 4	100mg Subcutaneous
Every 8 weeks	100mg Subcutaneous

2. Psoriatic Arthritis:

Week	Dosage
Week 0	100mg Subcutaneous
Week 4	100mg Subcutaneous
Every 8 weeks	100mg Subcutaneous

PUBLIC

Eligible Clinician Criteria:

Eligible Clinician Speciality
Dermatology
Rheumatology
Internal Medicine/Rheumatology

Requirements for Coverage

1. The Questionnaire must be filled out and submit the required documents for preauthorization request.
2. Failure to submit, upon request or when requesting a clinical history, an indication and the need for testing will result in the rejection of the claim.

Non-Coverage

1. Guselkumab is not covered when the above criteria (Coverage and Billing and CLN) are not met.
2. Coverage as per plan:

Plan	Coverage
Visitors Plan	Not covered
Basic	Covered
Enhanced	Covered
Thiqa	Covered

Payment and Coding Rules

Please apply DOH payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

Denial codes: DOH denial codes with description are elaborated for reference.

These are specialized codes directed by DOH, that explains the reason of rejection of the service by DAMAN to the providers.

Denial Code	Code description
MNEC 004	Service is not clinically indicated based on good clinical practice
MNEC 003	Diagnoses are not covered
CODE-010	Activity/diagnosis inconsistent with clinician's specialty

Questionnaire:

<https://www.damanhealth.ae/main/pdf/support/coverage-medical/Questionnaire/GuselkumabPre-authform.pdf>

PUBLIC

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	TEMP/349	Version No.:	1	Revision No.:	1	Date of Issue:	16.07.2019	Page No(s).:	3 of 5
---------------	----------	--------------	---	---------------	---	----------------	------------	--------------	--------

Appendices

Additional Information

JAWADA clinical quality KPI: not applicable

Questionnaire to be filled

Guselkumab Preauthorization Form

Section 1:

Member Information:

- Patient Name: _____
- Patient Card Number: _____

Section 2:

Kindly fill in the diagnosis field:

- Plaque Psoriasis
 Psoriatic Arthritis
 Other: _____

Is this a re-authorization request?

- Yes
 No

If yes, kindly provide prior requests completed and documentation regarding previous therapy.

If no, kindly complete the below clinical assessment:(If "Yes" has been selected, refer to section 3)

- Has the patient had an inadequate response to systemic therapy?
 Yes No
- Has the patient had an inadequate response to topical therapy?
 Yes No
- Does the patient have any contraindications to topical or systemic therapy?
 Yes No
- Has the patient undergone Tuberculosis screening? (If yes, kindly provide the laboratory test result)
 Yes No

Section 3:

- Previous drug therapy:(Specify name and dosage)

- Duration of previous therapy:

- Kindly specify the contraindicated drug (if applicable)

Section 4:

- Ordering clinician: _____
- Ordering Speciality: _____

Section 5:

Additional Comments:

Appendices

A. References

PUBLIC

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	TEMP/349	Version No.:	1	Revision No.:	1	Date of Issue:	16.07.2019	Page No(s).:	4 of 5
---------------	----------	--------------	---	---------------	---	----------------	------------	--------------	--------

- B. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf
C. <https://www.medicines.org.uk/emc/product/9587/smpc#gref>

D. Revision History

Date	Change(s)
27/12/22	Release of V1.0

PUBLIC

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	TEMP/349	Version No.:	1	Revision No.:	1	Date of Issue:	16.07.2019	Page No(s).:	5 of 5
---------------	----------	--------------	---	---------------	---	----------------	------------	--------------	--------